Atorvastatin in prevention of stroke and transient ischaemic attack

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 16, 2007, Pages 2789-2797

  Amarenco, Pierre ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Atorvastatin; Lipid lowering therapy; Statin; Stroke; Stroke prevention

Indexed keywords

AMLODIPINE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION PREVENTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; MYALGIA; MYOPATHY; POST HOC ANALYSIS; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CEREBROVASCULAR ACCIDENT; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; PYRROLES; RANDOMIZED CONTROLLED TRIALS;

EID: 36049012322     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.16.2789     Document Type: Article

References (28)

1. ROTHWELL PM, COULL AJ, SILVER LE et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet (2005) 366(9499):1773-1783.
2. GONGORA-RTVERA F, LABREUCHE J, JARAMILO A, STEG PG, HAUW J-J, AMARENCO P: The prevalence of coronary atherosclerosis in patients with stroke. Stroke (2007) 38:1203-1210.
3. DHAMOON MS, SCIACCA RR, RUNDEKT, SACCO RL, ELKIND MS: Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology (2006) 66(5):641-646.
4. SACCO RL, BENJAMIN EJ, BRODERICK JP et al.: American heart association prevention conference. IV. Prevention and rehabilitation of stroke. Risk Facton Stroke(1997) 28(7):1507-1517.
5. MACMAHON S: Blood pressure and the prevention of stroke. J. Hypertens. (1996) 14(S6):39-46.
6. AMARENCO P: LAVALLÉE P, TOUBOUL P-J: Stroke prevention, blood cholesterol, and statins. Lancet Neurol. (2004) 3:271-278.
7. AMARENCO P: The effects of statins in stroke prevention. Curr. Opin. Lipidol. (2005) 16:614-618.
8. AMARENCO P, LABREUCHE J, LAVALLEE P et al.: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke (2004) 35:2902-2909.
9. BAIGENT C, KEECH A, KEARNEY PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366:1267-1278.
10. LAROSA JC, GRUNDY SM, WATERS DD et al.: For the treating to new target (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. (2005) 352.
11. COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685-696.
12. SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361:1149-1158.
13. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361:2005-2016.
14. SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711-1718.
15. WATERS DD, SCHWARTZ GG, OLSSON AG et al.: Effects of atorvastarin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. Circulation (2002) 106:1690-1695.
16. ATHYROS VG, PAPAGEORGIOU AA, MERCOURIS BR et al.: Treatment with atorvastatin to the National cholesterol educational program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr Med. Res. Opin. (2002) 18:220-228.
17. KNOPP RH, D'EMDEN M, SMILDE JG, POCOCK SJ; ON BEHALF OF THE ASPEN STUDY GROUP: Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with Type 2 diabetes. Diabetes Care (2006) 29:1478-1485.
18. WANNER C, KRANE V, MARZ W et al.; FOR THE GERMAN DIABETES AND DIALYSIS STUDY INVESTIGATORS: Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. (2005) 353:238-248.
19. CANNON CP, BRAUNWALD E, MCCABE CH et al.; PRAVASTATIN OR ATORVASTATIN EVALUATION AND INFECTION THERAPY-THROMBOLYSIS IN MYOCARDIAL INFARCTION 22 INVESTIGATORS: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350(15):1495-1504.
20. WATERS DD, LAROSA JC, BARTER P et al.: Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J. Am. Coll. Cardiol. (2006) 48(9):1793-1799.
21. PEDERSEN TR, FAERGEMAN O, KASTELEIN JJP et al.: High-dose atoravastatin versus usual-dose simvastatin for secondary preventin after myocardial infatcion.The IDEAL study. a randomized controlled trial. JAMA (2005) 294:2427-2445.
22. KOREN MJ, HUNNINGHAKE DB; ON BEHALF OF THE ALLIANCE INVESTIGATORS: Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The ALLIANCE study. J. Am. Coll. Cardiol. (2004) 44:1772-1779.
23. HEART PROTECTION STUDY COLLABORATIVE GROUP: Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 363:757-767.
24. AMARENCO P, BOGOUSSLAVSKY J, CALLAHAN A III et al.; FOR THE SPARCL INVESTIGATORS: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. (2006) 355(6):549-555.
25. AMARENCO P, GOLDSTEIN LB, SZAREK M et al.; FOR THE SPARCL INVESTIGATORS: Effects of intense LDL-C reduction in patients with stroke or transient ischemic attack. the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke (2007) 38:(In Press).
26. GOLDSTEIN LB, AMARENCO P, SZAREK M et al.: Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology (2007) (In Press).
27. DE LEMOS JA, BLAZING MA, WIVIOTT SD et al.; FOR THE A TO Z INVESTIGATORS: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA (2004) 292:1307-1316.
28. MAZIGHI M, LAVALLÉE PC, LABREUCHE J, AMARENCO P: Statin in stroke prevention: what is known, what is new and what is next? Curr Opin. Lipidol.(2007) (In Press).